1998
DOI: 10.1038/bjc.1998.473
| |Summarize |Cite
|
Sign up to set email alerts

A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer

Abstract: Summary A phase trial of the combination of irinotecan (CPT-11) with cisplatin in advanced non-small cell lung cancer (NSCLC) showed a very promising response rate of 54% in previously untreated NSCLC patients. This study was conducted to confirm the activity and toxicities of CPT-11 and cisplatin combination for previously untreated NSCLC in a multi-institutional phase 11 study. Seventy patients with stage IIIB or IV NSCLC received CPT-11 60 mg m-2 intravenously (IV) on days 1, 8 and 15, and cisplatin 80 mg m… Show more

Search citation statements

Order By: Relevance

Paper Sections

Select...
51
12
7
0

Citation Types

2
42
1
0

Year Published

Range
1998
1998
2026
2026

Publication Types

Select...
63
1

Relationship

3
61

Authors

Journals

Cited by 64 publications

(45 citation statements)

References 27 publications

2
42
1
0
Order By: Relevance
How the paper below cites the one you are viewing
“…The treatment outcomes of the present study were superior or at least comparable to the results of previous multi-institutional trials of a combination of CPT-11 plus CDDP (Masuda et al, 1998(Masuda et al, , 1999DeVore et al, 1999;Niho et al, 1999). Recently, superiority of 2-drug combinations of one of the newly developed agents, vinorelbine or paclitaxel, with CDDP to the representative CDDP-based chemotherapy in the 1980s such as CDDP plus vindesine or etoposide was reported in prospective randomized trials (Le Chevalier et al, 1994;Bonomi et al, 2000).…”
Section: Discussion
supporting
confidence: 81%
“…British Journal of Cancer (2001) severe diarrhoea occurred in 25%, which was slightly higher than that in the previous reports (Masuda et al, 1998(Masuda et al, , 1999DeVore et al, 1999;Niho et al, 1999). In the weekly administration of both CPT-11 and CDDP conducted by Kobayashi et al under similar consideration (Kobayashi et al, 1998), the most prominent toxicity was leukopenia, and diarrhoea was not a dose-limiting toxicity.…”
Section: Discussion
mentioning
confidence: 58%
“…On the other hand, survival was fairly good. The MST (54 weeks) and 1-year survival rate (57%) were better than those reported previously with a combination of CPT-11 and CDDP (Masuda et al, 1998(Masuda et al, , 1999DeVore et al, 1999;Niho et al, 1999).…”
Section: Discussion
mentioning
confidence: 59%
See 2 more Smart Citations